Emergent BioSolutions Inc. (EBS) Financial Statements (2026 and earlier)

Company Profile

Business Address 300 PROFESSIONAL DR
GAITHERSBURG, MD 20879
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments205,40099,500111,700642,600576,100621,300
Cash and cash equivalent205,40099,500111,700642,600576,100621,300
Restricted cash and investments3,7006,100  200200
Receivables84,200154,500191,000159,200274,700230,900
Inventory, net of allowances, customer advances and progress billings343,400311,700328,900350,700350,800307,000
Inventory343,400311,700328,900350,700350,800307,000
Contract with customer, asset, after allowance for credit loss 6,4009,700  21,500 
Other undisclosed current assets19,40017,20047,90057,90048,80036,500
Total current assets:662,500598,700679,5001,210,4001,272,1001,195,900
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization205,400270,600382,800817,600800,100644,100
Intangible asset, including goodwill, after accumulated amortization436,500501,500566,600947,000829,500929,800
Goodwill    218,200224,900266,700
Intangible asset, excluding goodwill, after accumulated amortization436,500501,500566,600728,800604,600663,100
Other noncurrent assets14,20018,900194,300191,30057,300113,400
Total noncurrent assets:656,100791,0001,143,7001,955,9001,686,9001,687,300
TOTAL ASSETS:1,318,6001,389,7001,823,2003,166,3002,959,0002,883,200
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities67,80078,600130,800138,400269,300267,600
Employee-related liabilities✕✕✕✕✕88,70084,600
Accounts payable55,60060,900112,200103,500128,900136,100
Accrued liabilities12,20017,70018,60034,90051,70046,900
Deferred revenue5,0004,80027,20026,400  
Debt   413,700957,300  
Business combination, contingent consideration, liability   2,7003,400  
Other liabilities15,80027,70032,70045,90072,90083,100
Other undisclosed current liabilities43,60051,30044,20057,50031,60033,800
Total current liabilities:132,200162,400651,3001,228,900373,800384,500
Noncurrent Liabilities
Long-term debt and lease obligation572,100663,700446,500448,500809,400841,000
Long-term debt, excluding current maturities572,100663,700446,500448,500809,400841,000
Liabilities, other than long-term debt91,70080,80076,100101,200156,800210,700
Deferred revenue     4,70055,500
Deferred income tax liabilities37,80041,70047,20059,70094,90053,200
Other liabilities53,90039,10028,90041,50052,70067,800
Business combination, contingent consideration, liability     4,50034,200
Total noncurrent liabilities:663,800744,500522,600549,700966,2001,051,700
Total liabilities:796,000906,9001,173,9001,778,6001,340,0001,436,200
Equity
Equity, attributable to parent522,600482,800649,3001,387,7001,619,0001,447,000
Common stock100100100100100100
Treasury stock, value(252,600)(227,700)(227,700)(227,700)(152,200)(39,600)
Additional paid in capital942,400928,000904,400873,500829,400784,900
Accumulated other comprehensive income (loss)(7,500)(5,200)(5,700)3,100(16,100)(25,300)
Retained earnings (accumulated deficit)(159,800)(212,400)(21,800)738,700957,800726,900
Total equity:522,600482,800649,3001,387,7001,619,0001,447,000
TOTAL LIABILITIES AND EQUITY:1,318,6001,389,7001,823,2003,166,3002,959,0002,883,200

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues742,9001,043,6001,049,3001,117,5001,792,7001,555,400
Cost of revenue
(Cost of Product and Service Sold)
(326,200) (705,400)(693,100) (524,000)
Other undisclosed gross profit   (26,300)(41,400)  
Gross profit:416,7001,043,600317,600383,0001,792,7001,031,400
Operating expenses(642,800)(1,152,300)(1,775,700)(1,287,500)(1,440,100)(1,121,600)
Other undisclosed operating income326,200 731,700734,500 524,000
Operating income (loss):100,100(108,700)(726,400)(170,000)352,600433,800
Nonoperating expense(17,300)(34,200)(4,800)(49,000)(38,200)(26,600)
Other nonoperating income (expense)54,20012,5008,900(11,700)(3,700)4,700
Interest and debt expense(12,200)6002,500(37,300)(34,500)(31,300)
Other undisclosed income from continuing operations before equity method investments, income taxes      31,300
Income (loss) from continuing operations before equity method investments, income taxes:70,600(142,300)(728,700)(256,300)279,900407,200
Other undisclosed income (loss) from continuing operations before income taxes12,200(600)(2,500)37,30034,500 
Income (loss) from continuing operations before income taxes:82,800(142,900)(731,200)(219,000)314,400407,200
Income tax expense (benefit)(30,200)(47,700)(29,300)7,400(83,500)(102,100)
Income (loss) from continuing operations:52,600(190,600)(760,500)(211,600)230,900305,100
Income before gain (loss) on sale of properties:✕✕✕✕✕230,900305,100
Net income (loss) available to common stockholders, basic:52,600(190,600)(760,500)(211,600)230,900305,100
Dilutive securities, effect on basic earnings per share      
Net income (loss) available to common stockholders, diluted:52,600(190,600)(760,500)(211,600)230,900305,100

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):52,600(190,600)(760,500)(211,600)230,900305,100
Comprehensive income (loss):52,600(190,600)(760,500)(211,600)230,900305,100
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2,300)500(8,800)19,2009,200(15,400)
Comprehensive income (loss), net of tax, attributable to parent:50,300(190,100)(769,300)(192,400)240,100289,700

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: